Nephrology Division and.
Comprehensive Transplant Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
J Clin Invest. 2020 May 1;130(5):2189-2191. doi: 10.1172/JCI136475.
Immunosuppression continues to be a necessary component of transplantation, despite its association with a multitude of adverse effects. Numerous efforts have been made to circumvent the need for immunosuppression by using various techniques to achieve donor hyporesponsiveness. In this issue of the JCI, Morath et al. take this endeavor forward. Prior to transplantation, the researchers infused recipients with donor-modified immune cells and achieved immunologic hyporesponsiveness. This successful phase I trial also provides a possible avenue for achieving transplantation without the requisite immunosuppression.
尽管免疫抑制与多种不良反应相关，但它仍然是移植的必要组成部分。为了避免使用免疫抑制，人们已经尝试了许多方法来实现供体低反应性。在本期 JCI 中，Morath 等人将这一努力向前推进。在移植前，研究人员向受者输注供者修饰的免疫细胞，从而实现免疫低反应性。这项成功的 I 期试验也为实现无需免疫抑制的移植提供了一种可能的途径。
